<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39466600</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1744-8336</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>28</Day></PubDate></JournalIssue><Title>Expert review of anti-infective therapy</Title><ISOAbbreviation>Expert Rev Anti Infect Ther</ISOAbbreviation></Journal><ArticleTitle>Potential activity of nanomaterials to combat SARS-CoV-2 and Mucormycosis ‎coinfection‎.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1080/14787210.2024.2423359</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Mucormycosis, popularly known as the black fungus, has become a worldwide concern in the continuing COVID-19 pandemic, causing increased morbidity and death in immunocompromised people. Due to multi-drug resistance and the limited number of antifungals, surgical interventions, ‎including the excision of infected tissue, remain a standard treatment option‎. Surgical treatment usually results in the loss of organs or their function, long-term intensive care, and a significant risk of reinfection during the procedure. A comprehensive approach is needed to treat the disease, and nanomaterials can be a powerful alternative therapeutic approach.</AbstractText><AbstractText Label="AREAS COVERED" NlmCategory="UNASSIGNED">We searched PubMed, Scopus, and Google Scholar with the keywords 'emerging role of nanomaterials,' and 'combating COVID-19-related mucormycosis,' and reviewed the related research paper. Antifungal nanomaterials and their delivery can significantly impact the treatment of COVID-19-related fungal infections like mucormycosis. However, the therapeutic options for mucormycosis are limited and drug resistance is also reported.</AbstractText><AbstractText Label="EXPERT OPINION" NlmCategory="UNASSIGNED">The current review encompasses a detailed overview of the recent developments in antifungal/antiviral nanomaterials and the properties of these therapeutic nanomaterials that may contribute to formulating an efficient strategy against invasive mucormycosis. Further extensive research is needed to develop nano-based therapeutics for the management of mucormycosis-viral coinfection with a definitive end-point.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mahapatra</LastName><ForeName>Chinmaya</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biotechnology, National Institute of Technology (NIT), Raipur, Chhattisgarh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jadhav</LastName><ForeName>Sakshi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biotechnology and Medical Engineering, National Institute of Technology (NIT), Rourkela, Odisha, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Prasoon</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Biotechnology and Medical Engineering, National Institute of Technology (NIT), Rourkela, Odisha, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roy</LastName><ForeName>Dijendra Nath</ForeName><Initials>DN</Initials><AffiliationInfo><Affiliation>Department of Biotechnology, National Institute of Technology (NIT), Raipur, Chhattisgarh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Awanish</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biotechnology, National Institute of Technology (NIT), Raipur, Chhattisgarh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paul</LastName><ForeName>Manash K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Rev Anti Infect Ther</MedlineTA><NlmUniqueID>101181284</NlmUniqueID><ISSNLinking>1478-7210</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antifungal/Antiviral therapeutics</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Nanomaterial</Keyword><Keyword MajorTopicYN="N">Pathogenesis</Keyword><Keyword MajorTopicYN="N">mucormycosis (black fungus)</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>28</Day><Hour>18</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>28</Day><Hour>18</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>28</Day><Hour>12</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39466600</ArticleId><ArticleId IdType="doi">10.1080/14787210.2024.2423359</ArticleId></ArticleIdList></PubmedData></PubmedArticle>